CANGRELOR (cangrelor) by Gland Pharma is p2y12 receptor antagonists [moa]. Approved for p2y12 platelet inhibitor [epc]. First approved in 2025.
Drug data last refreshed 1w ago
P2Y12 Receptor Antagonists
P2Y12 Platelet Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not
Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock
Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor
ARCANGELO (itAlian pRospective Study on CANGrELOr)
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
Worked on CANGRELOR at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.